Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
J Adolesc Young Adult Oncol ; 13(3): 523-533, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38416604

ABSTRACT

Purpose: This study's aim was to determine the actual status of transitional care for patients with pediatric cancer (PPCs) in Japan by surveying obstetricians/gynecologists. Methods: A questionnaire survey on transitional medicine was conducted in the form of an online questionnaire at 579 major training facilities nationwide, which were registered with the Japanese Society of Obstetrics and Gynecology. Results: While 40% of the facilities had received referrals for PPCs, only 13% provided transitional care specifically for PPCs. The most common problems with referrals were related to "insufficient explanation." In addition, at facilities with no experience treating PPCs, many respondents commented that they did not know how to follow the progression of the disease. Regarding the necessity of obstetrics/gynecology visits for PPCs, more than half of the respondents at facilities with experience treating PPCs answered that such visits were "necessary"; only 1% answered that they were "unnecessary." On the other hand, 37% of the facilities that had no experience treating PPCs answered that it was "necessary," whereas 4% answered that it was "unnecessary." Conclusions: This survey of the actual status of transitional care between pediatrics and obstetrics/gynecology in Japan identified issues to be addressed for the spread of transitional care. The results suggest that, in the future, health care professionals need education to increase their knowledge, and that patient education that leads to patients' awareness of their own self-management is necessary.


Subject(s)
Gynecology , Obstetrics , Pediatrics , Transitional Care , Humans , Japan , Female , Surveys and Questionnaires , Male , Adult
4.
Oncology ; 99(1): 23-31, 2021.
Article in English | MEDLINE | ID: mdl-32906115

ABSTRACT

OBJECTIVE: Most types of intracranial germ cell tumors (IGCTs) are sensitive to chemoradiation. However, biopsy specimens are usually small and thus cannot be used for obtaining an accurate pathological diagnosis. Recently, the cerebrospinal fluid (CSF) placental alkaline phosphatase (PLAP) value has been considered a new biomarker of IGCTs. The present study aimed to evaluate the discriminatory characteristics of the CSF-PLAP value upon diagnosis and at the time of recurrence in patients with IGCTs. METHODS: Between 2015 and 2019, this study included 37 patients with tumors located in the intraventricular and/or periventricular region. The CSF-PLAP level was assessed before the patients received any treatment. The PLAP level was evaluated during and after first-line chemoradiotherapy in 7 patients with IGCTs. The CSF-PLAP values were compared according to histological diagnosis, and the correlation between these values and radiographical features was assessed. The CSF-PLAP values of 6 patients with IGCTs with suspected recurrence were evaluated based on neuroimaging findings. RESULTS: The CSF-PLAP values were significantly higher in patients with IGCTs than in those with other types of brain tumor (n = 19 vs. 18; median: 359.0 vs. <8.0 pg/mL). The specificity and sensitivity were 88 and 95%, respectively, with a cutoff value of 8.0 pg/mL. In patients with IGCT, the CSF-PLAP value was higher in patients with germinoma than in those with nongerminomatous germ cell tumors (n = 12 vs. 7; median: 415.0 vs. 359.0 pg/mL). Regarding the time course, the CSF-PLAP value decreased to below the detection limit after the reception of first-line chemoradiotherapy in all 7 patients. A significant correlation was observed between the initial CSF-PLAP value and the tumor reduction volume after receiving first-line chemoradiotherapy (p < 0.0003, R2 = 0.6165, logY = 1.202logX - 1.727). Among the patients with suspected IGCT recurrence (n = 6), the CSF-PLAP value was high in patients with recurrence (n = 3; median: 259.0 pg/mL), and that in patients (n = 3) without recurrence was below the lower detection limit. CONCLUSIONS: The CSF-PLAP level is a useful biomarker during the initial diagnosis of IGCTs and at the time of recurrence. It may be associated with the volume of germinomatous components of tumors.


Subject(s)
Alkaline Phosphatase/cerebrospinal fluid , Biomarkers, Tumor/cerebrospinal fluid , Brain Neoplasms/cerebrospinal fluid , Isoenzymes/cerebrospinal fluid , Neoplasms, Germ Cell and Embryonal/cerebrospinal fluid , Adolescent , Adult , Brain Neoplasms/enzymology , Brain Neoplasms/pathology , Child , Child, Preschool , GPI-Linked Proteins/cerebrospinal fluid , Germinoma/cerebrospinal fluid , Germinoma/pathology , Humans , Male , Neoplasm Recurrence, Local/cerebrospinal fluid , Neoplasm Recurrence, Local/pathology , Neoplasms, Germ Cell and Embryonal/enzymology , Neoplasms, Germ Cell and Embryonal/pathology , Young Adult
7.
J Pediatr Hematol Oncol ; 42(8): e791-e794, 2020 11.
Article in English | MEDLINE | ID: mdl-32049768

ABSTRACT

We report an 18-year-old female individual with septic arthritis due to Mycobacterium kansasii. Three years and 6 months before arthritis, the patient underwent bone marrow transplantation and developed severe chronic graft-versus-host disease. The arthritis was refractory to medication, and she underwent joint lavage of the right foot, hip joint, and elbow joint. After surgery, her joint symptoms were relieved, and chronic graft-versus-host disease remitted more easily. It is important that we maintain a high index of suspicion for mycobacterial arthritis and diagnose it early when immunosuppressed patients experience chronic pain and joint swelling.


Subject(s)
Arthritis, Infectious/epidemiology , Bone Marrow Transplantation/adverse effects , Graft vs Host Disease/etiology , Mycobacterium Infections, Nontuberculous/complications , Mycobacterium kansasii/pathogenicity , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Anti-Bacterial Agents/therapeutic use , Arthritis, Infectious/drug therapy , Arthritis, Infectious/microbiology , Female , Graft vs Host Disease/pathology , Humans , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium kansasii/drug effects , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Prognosis
8.
Pediatr Blood Cancer ; 66(12): e27977, 2019 12.
Article in English | MEDLINE | ID: mdl-31489974

ABSTRACT

BACKGROUND: Corticosteroids, especially dexamethasone, play a critical role in chemotherapy for pediatric hematological malignancies. We previously observed that patients with complaints of headache or photophobia during corticosteroid administration had high intraocular pressure (IOP). PROCEDURE: We measured IOP during corticosteroid administration in 15 patients with acute leukemia or lymphoma undergoing treatment at our institution from January 2016 to December 2018. IOP was measured by an ophthalmologist within seven days of the initiation of standard dose of corticosteroid, which was defined as 60 mg/m2 /day for prednisolone and 10 mg/m2 /day for dexamethasone. RESULTS: Fifteen patients received 52 courses of chemotherapy containing corticosteroids. IOP exceeded 21 mmHg among 13 patients in 28 courses. Twelve of the 13 patients were administered topical treatment, and six of the 12 patients needed additional diuretic agents. IOP during the chemotherapy courses containing dexamethasone was significantly higher compared with IOP during the chemotherapy courses containing prednisolone. Only two patients complained of symptoms, such as headache and photophobia, and one of the two patients underwent trabeculotomy. Funduscopic findings were normal in all patients. There was a dose-associated decrease in IOP with reduction of dexamethasone dose. CONCLUSIONS: IOP should be measured during administration of substantial corticosteroid doses even in patients with no symptoms. Further investigations regarding the level of IOP for intervention need to be conducted.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Glaucoma/chemically induced , Hematologic Neoplasms/drug therapy , Intraocular Pressure/drug effects , Visual Acuity/drug effects , Adolescent , Adrenal Cortex Hormones/administration & dosage , Child , Child, Preschool , Dexamethasone/administration & dosage , Female , Follow-Up Studies , Glaucoma/epidemiology , Hematologic Neoplasms/pathology , Humans , Male , Prednisolone/administration & dosage , Prognosis , Retrospective Studies
9.
J Clin Virol ; 116: 34-38, 2019 07.
Article in English | MEDLINE | ID: mdl-31082730

ABSTRACT

BACKGROUND: Echovirus 30 (E30) is one of the most common causative agents for aseptic meningitis. OBJECTIVES: In the autumn of 2017, there was an outbreak caused by E30 in Kushiro, Hokkaido, Japan. The aim of this study was to characterize this outbreak. STUDY DESIGN: Fifty-nine patients were admitted to the Department of Pediatrics, Kushiro Red Cross Hospital (KRCH) with clinical diagnosis of aseptic meningitis. Among those, 36 patients were finally diagnosed as E30-associated aseptic meningitis by the detection of viral RNA using reverse transcription-polymerase chain reaction (RT-PCR) and/or the evidence of more than four-fold rise in neutralizing antibody (NA) titers in the convalescent phase relative to those in the acute phase. We investigated these 36 confirmed cases. RESULTS: The median age was 6 years (range: 6 months-14 years). The positive signs and symptoms were as follows: fever (100%), headache (94%), vomiting (92%), jolt accentuation (77%), neck stiffness (74%), Kernig sign (29%), and abdominal pain (28%). The median cerebrospinal fluid (CSF) white cell count, neutrophil count, and lymphocyte count were 222/µL (range: 3-1434/µL), 144/µL (range: 1-1269/µL), and 85/µL (range: 2-354/µL), respectively. Although the detected viral genes demonstrated same cluster, they were different from E30 strains observed in Japan between 2010 and 2014. CONCLUSION: We mainly showed clinical and virological features of the E30-associated aseptic meningitis outbreak that occurred in Kushiro. To prevent further spread of E30 infection, continuous surveillance of enterovirus (EV) circulation and standard precautions are considered essential.


Subject(s)
Disease Outbreaks , Echovirus Infections/epidemiology , Echovirus Infections/virology , Enterovirus B, Human/isolation & purification , Meningitis, Aseptic/epidemiology , Meningitis, Aseptic/virology , Adolescent , Antibodies, Neutralizing/blood , Cerebrospinal Fluid/cytology , Child , Child, Preschool , Echovirus Infections/pathology , Echovirus Infections/physiopathology , Enterovirus B, Human/classification , Enterovirus B, Human/genetics , Enterovirus B, Human/immunology , Female , Genotype , Hospitals, Pediatric , Humans , Infant , Japan/epidemiology , Male , Meningitis, Aseptic/pathology , Meningitis, Aseptic/physiopathology , Phylogeny , RNA, Viral/genetics , Viral Proteins/genetics
10.
Pediatr Blood Cancer ; 66(2): e27478, 2019 02.
Article in English | MEDLINE | ID: mdl-30350912

ABSTRACT

BACKGROUND: Stem cell transplantation (SCT) outcomes have improved over the last three decades, with many patients being rescued with this treatment. However, improved outcomes have led to issues with long-term sequelae. One of these sequelae in children is renal dysfunction, an index of which is estimated using glomerular filtration rate (eGFR). PROCEDURE: We retrospectively analyzed eGFR in 83 pediatric patients who received SCT. Data from all patients extended up to 12 months or more post SCT. The median follow-up time was 127.7 months (range 12.0-268.8 months). RESULTS: Eighteen patients (21.7%) had low eGFR (<90 ml/min/1.73 m2 ) post SCT. Cumulative incidence of low eGFR was 25.8 ± 2.0%. Nine (10.6%) patients had a low eGFR pre-SCT. However, pre- and post-SCT incidence of low eGFR were not correlated. Meanwhile, only two patients (2.4%) exhibited severe renal dysfunction, with eGFRs < 60 ml/min/1.73 m2 . Independent risk factors for low eGFR were solid tumor and use of fludarabine. Moreover, age at SCT ≥ 7 years was also a long-term post-SCT risk factor for low eGFR in all patients. CONCLUSION: Independent post-SCT long-term risk factors for low eGFR in children were solid tumor and use of fludarabine. Moreover, age at SCT ≥ 7 years was a post-SCT long-term risk factor for low eGFR across all patients.


Subject(s)
Glomerular Filtration Rate , Hematopoietic Stem Cell Transplantation/adverse effects , Kidney Diseases/epidemiology , Neoplasms/drug therapy , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Incidence , Infant , Infant, Newborn , Kidney Diseases/etiology , Male , Retrospective Studies , Young Adult
11.
Pediatr Int ; 61(3): 230-234, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30570800

ABSTRACT

BACKGROUND: Central venous (CV) catheters are required for chemotherapy but they may become a source of life-threatening infections of the bloodstream. The most effective way to disinfect the port of a CV catheter has not been established. METHODS: We report the data obtained between April 2008 and March 2010 using 83% ethanol (period I) and between April 2010 and March 2014 using 10% povidone-iodine (period II) to sterilize the access port. The participants received chemotherapy or autologous/allogeneic stem cell transplantation at the present institution. RESULTS: No significant difference was observed in patient characteristics between the two periods, such as disease, median age, or the period of neutropenia. The incidence of positive blood culture during periods I and II was 18.5% (31/168) and 11.4% (40/350; P = 0.041), respectively. The incidence of catheter-associated bloodstream infection on blood culture during periods I and II was 11.9% (20/168) and 6.3% (22/350; P = 0.043), respectively. Bacillus cereus infection was not detected during period II. CONCLUSION: The incidence of infection caused by CV catheters was significantly reduced using povidone-iodine; therefore, we recommend this procedure as part of the routine in chemotherapy.


Subject(s)
Anti-Infective Agents, Local/administration & dosage , Bacteremia/epidemiology , Catheter-Related Infections/prevention & control , Catheterization, Central Venous/adverse effects , Povidone-Iodine/administration & dosage , Adolescent , Adult , Bacteremia/etiology , Bacteremia/prevention & control , Blood Culture/methods , Catheter-Related Infections/epidemiology , Catheter-Related Infections/microbiology , Child , Child, Preschool , Ethanol/administration & dosage , Febrile Neutropenia , Female , Humans , Incidence , Infant , Infant, Newborn , Male , Retrospective Studies , Sterilization/methods , Young Adult
12.
Int J Hematol ; 106(2): 291-298, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28401497

ABSTRACT

Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m2/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration-time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80%). In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Induction Chemotherapy , Leukemia, B-Cell/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Asian People , Bortezomib/administration & dosage , Bortezomib/adverse effects , Bortezomib/pharmacokinetics , Child , Child, Preschool , Communicable Diseases/etiology , Humans , Infant , Neutropenia/chemically induced , Risk
13.
Pediatr Transplant ; 20(1): 114-9, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26526424

ABSTRACT

GVHD and graft failure are serious problems in CBT. PES after CBT also occurs frequently and is associated with transplantation-related complications such as acute GVHD. We reviewed medical records for 70 consecutive child CBT recipients between December 1997 and April 2015. Forty-nine patients received prophylaxis against GVHD with CsA or Tac in combination with mPSL from day +7 (mPSL group), and 21 patients received CsA or Tac with MTX on day +1 and day +3 (MTX group). Neutrophil engraftment was detected in 59 patients (84.3%). Neutrophil engraftment rate in the MTX group was significantly higher than that in the mPSL group (21/21 (100%) and 38/49 (77.6%), respectively, p = 0.027). PES developed in 35 patients, and the incidence of PES in the mPSL group was significantly higher than that in the MTX group (p = 0.036). The incidence of severe acute GVHD (grade III or IV) in the MTX group was significantly lower than that in the mPSL group (p = 0.049). Although this study was a small-scale study, the results showed that increase in the rate of engraftment and decrease in the incidence of early immune reactions such as PES and severe acute GVHD could be achieved by early commencement of immunosuppression using MTX.


Subject(s)
Cord Blood Stem Cell Transplantation , Graft vs Host Disease/diagnosis , Graft vs Host Disease/prevention & control , Methotrexate/therapeutic use , Neoplasms/therapy , Adolescent , Child , Child, Preschool , Cyclosporine/administration & dosage , Disease-Free Survival , Female , Graft Survival , Graft vs Host Disease/epidemiology , Humans , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Incidence , Infant , Infant, Newborn , Male , Neutrophils/metabolism , Retrospective Studies , Tacrolimus/administration & dosage , Time Factors , Transplantation Conditioning , Treatment Outcome
14.
Brain Dev ; 34(9): 784-6, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22277190

ABSTRACT

Anti-muscle-specific tyrosine kinase antibody (MuSK-Ab) is the second most frequent autoantibody identified in adult patients with myasthenia gravis (MG). Adult patients with MuSK-Ab demonstrate characteristic clinical features but very little information is available for childhood-onset patients with MuSK-positive MG. We report a childhood-onset female patient with MuSK-positive MG. This patient showed basic clinical features compatible with adult-onset MuSK-positive MG, but some features, including spontaneous improvement, are distinct from those in adult patients. Serial examination of MuSK-Ab titers revealed a gross correlation with clinical severity despite significantly high titers throughout the clinical course. Therefore, childhood-onset MuSK-positive MG may demonstrate a distinct clinical characteristics in the early period of illness.


Subject(s)
Autoantibodies/blood , Myasthenia Gravis/blood , Receptor Protein-Tyrosine Kinases/immunology , Child , Disease Progression , Electric Stimulation , Electromyography , Female , Humans , Muscle, Skeletal/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...